90 related articles for article (PubMed ID: 17128465)
21. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population.
Sun S; Greenwood CM; Thiffault I; Hamel N; Chong G; Foulkes WD
J Med Genet; 2005 Oct; 42(10):766-8. PubMed ID: 16199548
[TBL] [Abstract][Full Text] [Related]
22. Gene symbol: hMSH. Disease: Hereditary nonpolyposis colorectal cancer.
Sun MH; Cai Q; Fu G; Ren S; Mo S; Xu Y; Ding C; Zhang T; Zhu X; Xu X; Min D; Cai S; Luo D; Shi Y; Shi D
Hum Genet; 2004 Mar; 114(4):409. PubMed ID: 15046092
[No Abstract] [Full Text] [Related]
23. The 10-Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: re-annotation and mutational mechanisms.
Chen JM
Genes Chromosomes Cancer; 2008 Jun; 47(6):543-5. PubMed ID: 18335504
[No Abstract] [Full Text] [Related]
24. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
[TBL] [Abstract][Full Text] [Related]
25. Gene symbol: msh2. Disease: MSH2.
Colombino M
Hum Genet; 2004 Jul; 115(2):173. PubMed ID: 15300982
[No Abstract] [Full Text] [Related]
26. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
[TBL] [Abstract][Full Text] [Related]
27. A database to support the interpretation of human mismatch repair gene variants.
Ou J; Niessen RC; Vonk J; Westers H; Hofstra RM; Sijmons RH
Hum Mutat; 2008 Nov; 29(11):1337-41. PubMed ID: 18951442
[TBL] [Abstract][Full Text] [Related]
28. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
29. Six primary cancers in one Lynch syndrome patient with chronic arsenic exposure.
Chen PC; Chen WC; Chao SC; Lin BW; Lin SC; Chen CJ; Lee JC
J Surg Oncol; 2012 Mar; 105(3):329-30. PubMed ID: 21882197
[No Abstract] [Full Text] [Related]
30. Solitary subungual keratoacanthoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis.
Stoebner PE; Fabre C; Delfour C; Joujoux JM; Roger P; Dandurand M; Meunier L
Dermatology; 2009; 219(2):174-8. PubMed ID: 19602866
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer in a 9-year-old due to combined EPCAM and MSH2 germline mutations: case report of a unique genotype and immunophenotype.
Li-Chang HH; Driman DK; Levin H; Siu VM; Scanlan NL; Buckley K; Cairney AE; Ainsworth PJ
J Clin Pathol; 2013 Jul; 66(7):631-3. PubMed ID: 23454724
[No Abstract] [Full Text] [Related]
32. Gene symbol: APC. Disease: colorectal cancer.
Tan LP; Ng BK; Balraj P; Poh BH; Lim PK; Peh SC
Hum Genet; 2005 Dec; 118(3-4):545. PubMed ID: 16521296
[No Abstract] [Full Text] [Related]
33. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
[TBL] [Abstract][Full Text] [Related]
34. Origins and prevalence of the American Founder Mutation of MSH2.
Clendenning M; Baze ME; Sun S; Walsh K; Liyanarachchi S; Fix D; Schunemann V; Comeras I; Deacon M; Lynch JF; Gong G; Thomas BC; Thibodeau SN; Lynch HT; Hampel H; de la Chapelle A
Cancer Res; 2008 Apr; 68(7):2145-53. PubMed ID: 18381419
[TBL] [Abstract][Full Text] [Related]
35. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients.
Hampel H; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; LaJeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; de la Chapelle A; Frankel W; Penzone P; Cohn DE; Copeland L; Eaton L; Fowler J; Lombardi J; Dunn P; Bell J; Reid G; Lewandowski G; Vaccarello L
Cancer Res; 2007 Oct; 67(19):9603. PubMed ID: 17909073
[No Abstract] [Full Text] [Related]
36. Multiplexed assays reveal effects of missense variants in MSH2 and cancer predisposition.
Nielsen SV; Hartmann-Petersen R; Stein A; Lindorff-Larsen K
PLoS Genet; 2021 Apr; 17(4):e1009496. PubMed ID: 33886538
[No Abstract] [Full Text] [Related]
37. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome).
Lynch HT; Lynch JF; Lynch PM
J Natl Cancer Inst; 2007 Feb; 99(4):261-3. PubMed ID: 17312298
[No Abstract] [Full Text] [Related]
38. Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier.
Vaknin Z; Gotlieb WH; Arseneau J; Ferenczy A
Int J Gynaecol Obstet; 2009 Oct; 107(1):68-9. PubMed ID: 19545867
[No Abstract] [Full Text] [Related]
39. Development of a Premature Stop Codon-detection method based on a bacterial two-hybrid system.
Real SM; Marzese DM; Gomez LC; Mayorga LS; Roqué M
BMC Biotechnol; 2006 Sep; 6():38. PubMed ID: 16948859
[TBL] [Abstract][Full Text] [Related]
40. Enhanced gene targeting to evaluate Lynch syndrome alterations.
Fishel R; Heinen CD
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):3918-20. PubMed ID: 27035997
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
